MedPath

Virchow Group

🇮🇳India
Ownership
Private
Employees
-
Market Cap
-
Website
http://www.virchows.com

Clinical Trials

5

Active:0
Completed:4

Trial Phases

2 Phases

Phase 1:1
Phase 3:4

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials

Phase 3
4 (80.0%)
Phase 1
1 (20.0%)

Efficacy, Safety and Pharmacokinetic of Virchow IVIG in PID Patients

Phase 3
Not yet recruiting
Conditions
Primary Immunodeficiency Diseases (PID)
Interventions
Drug: IVIG-VImmune
Drug: IVIG-Immuglo
First Posted Date
2025-06-12
Last Posted Date
2025-06-12
Lead Sponsor
Virchow Group
Target Recruit Count
44
Registration Number
NCT07017036
Locations
🇮🇳

All India Institute of Medical Sciences, Nagpur, Maharastra, India

🇮🇳

Jyoti Nursing Home (P) Ltd., Jaipur, Rajasthan, India

Comparative Study of 3 Dose Regimens of BioChaperone to Becaplermin Gel for the Treatment of Diabetic Foot Ulcer

Phase 1
Completed
Conditions
Diabetic Foot Ulcers
Interventions
Drug: Biochaperone PDGF-BB High dose
Drug: Biochaperone PDGF-BB Very Low Dose
Drug: Biochaperone PDGF-BB Low dose
First Posted Date
2010-04-02
Last Posted Date
2014-12-15
Lead Sponsor
Virchow Group
Target Recruit Count
192
Registration Number
NCT01098357
Locations
🇮🇳

Vijay Vachharajani Memorial, Rajkot, Gujarat, India

🇮🇳

Jain Institute of Vascular sciences, Bangalore, Karnataka, India

🇮🇳

Karnataka Institute of Diabetology, Bangalore, Karnataka, India

and more 4 locations

Safety and Efficacy of TULY (Rasburicase) in Prevention and Treatment of Malignancy-associated Hyperuricemia

Phase 3
Completed
Conditions
Hyperuricemia
Interventions
First Posted Date
2009-06-16
Last Posted Date
2014-12-12
Lead Sponsor
Virchow Group
Target Recruit Count
100
Registration Number
NCT00921375
Locations
🇮🇳

Dr. Raghunathrao, Hyd, Andhra Pradesh, India

Safety and Efficacy of OSTEOFORM (rhPTH [1-34]) in Increasing Bone Mineral Density in Osteoporosis

Phase 3
Completed
Conditions
Osteoporosis
Interventions
Drug: Osteoform
Drug: SHELCAL
First Posted Date
2007-07-12
Last Posted Date
2014-12-16
Lead Sponsor
Virchow Group
Target Recruit Count
82
Registration Number
NCT00500409
Locations
🇮🇳

Apollo Hospitals, Chennai, Tamil Nadu, India

🇮🇳

CARE Hospitals, Hyderabaad, Andhra Pradesh, India

🇮🇳

Medwin Hospital, Hyderabaad, Andhra Pradesh, India

and more 2 locations

Efficacy and Safety of PERIOGEN in the Treatment of Periodontal Bone Defect

Phase 3
Completed
Conditions
Intrabony Periodontal Defect
Interventions
Drug: Beta TCP alone
First Posted Date
2007-07-04
Last Posted Date
2014-12-16
Lead Sponsor
Virchow Group
Target Recruit Count
60
Registration Number
NCT00496847
Locations
🇮🇳

Sri Sai Dental college of surgery, Vikarabad,, RR Dist, Andhra pradesh, India

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.